{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06225115",
            "orgStudyIdInfo": {
                "id": "KYN5356-CL-001"
            },
            "organization": {
                "fullName": "Kynexis B.V.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years",
            "officialTitle": "A First in Human Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of KYN-5356 in Adult, Healthy Subjects",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "a-study-to-investigate-the-safety-tolerability-and-pharmacokinetics-of-kyn-in-healthy-subjects-aged-to-years"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-20",
            "studyFirstSubmitQcDate": "2024-01-16",
            "studyFirstPostDateStruct": {
                "date": "2024-01-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kynexis B.V.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Parexel",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.\n\nThe study comprises 3 parts:\n\nPart 1: Single Ascending Dose study Part 2: Multiple Ascending Dose study Part 3: Food Effect study\n\nThe aim of Parts 1 and 2 of the study is to evaluate the safety and tolerability following single and multiple ascending doses of KYN-5356.\n\nThe secondary aim is to evaluate the pharmacokinetics (PK) of escalating single and multiple doses of KYN-5356. In Part 2, cerebrospinal fluid will be sampled to explore PK and pharmacodynamic effects of KYN-5356.\n\nThe potential effect of food intake on the disposition of KYN-5356 following a single oral dose will be evaluated in Part 3. Part 3 is an open-label, randomized, 2 period, 2 sequence design."
        },
        "conditionsModule": {
            "conditions": [
                "Cognitive Dysfunction",
                "Schizophrenia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SAD Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 1. Intervention: KYN-5356 A mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "SAD Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 2. Intervention: KYN-5356 B mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "SAD Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 3. Intervention: KYN-5356 C mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "SAD Cohort 4",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 4. Intervention: KYN-5356 D mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "SAD Cohort 5",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 5. Intervention: KYN-5356 E mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "SAD Cohort 6",
                    "type": "EXPERIMENTAL",
                    "description": "Single-Ascending Dose Cohort 6. Intervention: KYN-5356 F mg or placebo, single dose, oral tablet",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "MAD Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple-Ascending Dose Cohort 1. Intervention: KYN-5356 G mg or placebo, oral tablets for 7 days",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "MAD Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple-Ascending Dose Cohort 2. Intervention: KYN-5356 H mg or placebo, oral tablets for 7 days",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "MAD Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple-Ascending Dose Cohort 3. Intervention: KYN-5356 I mg or placebo, oral tablets for 7 days",
                    "interventionNames": [
                        "Drug: KYN-5356",
                        "Drug: placebo"
                    ]
                },
                {
                    "label": "Food Effect Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Intervention: KYN-5356 J mg, single dose, oral tablets in fasted or fed state.",
                    "interventionNames": [
                        "Drug: KYN-5356"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "KYN-5356",
                    "description": "KYN-5356, oral tablet",
                    "armGroupLabels": [
                        "Food Effect Cohort",
                        "MAD Cohort 1",
                        "MAD Cohort 2",
                        "MAD Cohort 3",
                        "SAD Cohort 1",
                        "SAD Cohort 2",
                        "SAD Cohort 3",
                        "SAD Cohort 4",
                        "SAD Cohort 5",
                        "SAD Cohort 6"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "placebo",
                    "description": "placebo, oral tablet",
                    "armGroupLabels": [
                        "MAD Cohort 1",
                        "MAD Cohort 2",
                        "MAD Cohort 3",
                        "SAD Cohort 1",
                        "SAD Cohort 2",
                        "SAD Cohort 3",
                        "SAD Cohort 4",
                        "SAD Cohort 5",
                        "SAD Cohort 6"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Treatment-Emergent Adverse Events",
                    "description": "All cohorts",
                    "timeFrame": "Initiation of dosing through the last follow-up visit after the last dose, approximately 8 days in the MAD and 5 days after dosing in the SAD and the Food Effect parts of the study"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK parameters: Cmax [SAD]",
                    "description": "Maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing"
                },
                {
                    "measure": "PK parameters: tmax [SAD]",
                    "description": "Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing"
                },
                {
                    "measure": "PK parameters: AUCinf [SAD]",
                    "description": "Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in SAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing"
                },
                {
                    "measure": "PK parameters: Cmax on Day 1 [MAD]",
                    "description": "Maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part",
                    "timeFrame": "Baseline (predose) through 24 hours post first dosing"
                },
                {
                    "measure": "PK parameters: tmax on Day 1 [MAD]",
                    "description": "Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part.",
                    "timeFrame": "Baseline (predose) through 24 hours post first dosing"
                },
                {
                    "measure": "PK parameters: Cmax,ss [MAD]",
                    "description": "Maximum observed plasma concentration during a dosing interval at steady state. For each dose in MAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing on Day 7."
                },
                {
                    "measure": "PK parameters: tmax,ss [MAD]",
                    "description": "Time of maximum plasma concentration determined directly from the concentration-time profile at steady state. For each dose in MAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing on Day 7."
                },
                {
                    "measure": "PK parameters: AUCinf [MAD]",
                    "description": "Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in MAD part.",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing on Day 7."
                },
                {
                    "measure": "PK parameters: AUCtau on Days 1 and 7 [MAD]",
                    "description": "Area under the concentration-time curve over the dosing interval. For each dose in MAD part",
                    "timeFrame": "Baseline (predose) through 72 hours post dosing on Day 7."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject understands the study procedures and agrees to participate by providing written informed consent prior to any study procedures.\n* Subject is between 18 and 55 years of age (inclusive), on the date of signing the informed consent form.\n* Subject has a body mass index between 18 and 30 kg/m2, inclusive.\n* A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance (highly effective birth control method) from Screening until end of the study. Note: Males should use appropriate contraceptive method from Screening until end of the study.\n* Subject is judged to be in good health by the Principal Investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory safety tests.\n* Subject is willing to adhere to the study requirements and restrictions.\n\nExclusion Criteria:\n\n* Subject has positive serology for HBsAg, HCV, or HIV, or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the Investigational Medicinal Product.\n* Subject has any illness judged by the Principal Investigator as clinically significant, in the 3 months prior to first dosing of the Investigational Medicinal Product.\n* Subject has a suicidality score of \"yes\" on item 4 or item 5 of the suicidal ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or \"yes\" on any item of the suicidal behavior section, except for the \"Non-Suicidal Self-Injurious Behavior\" (item also included in the suicidal behavior section), if this behavior occurred in the past 2 years.\n* Subject has a history or current sign or symptom of psychiatric or neurologic disease.\n* Subject has a history of head trauma in the past year and/or current seizures.\n* Subject is a smoker (use of tobacco products in the previous 3 months from Screening) or uses nicotine or nicotine-containing products and has a positive urine cotinine test at Screening or Admission.\n* Subject has a history of alcohol and/or illicit drug abuse within 2 years of entry or has a positive screening test for alcohol and/or drugs of abuse at Screening or Admission.\n* Subject consumes caffeine containing beverages exceeding 500 mg caffeine per day (5 cups of coffee) during the off-site days during the study.\n* Subject has regular excessive consumption of alcohol within 6 months prior to Screening (7 drinks/week for females, 14 drinks/week for males where 1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor).\n* Subject has a history or current sign or symptom of a cardiovascular, renal, or metabolic bone disease or disease of bone remodeling, or any history of endocrine disease, including an abnormal laboratory result for pre-specified clinical laboratory safety parameters related to these conditions.\n* Subject has a history or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction. A first-degree atrioventricular block will not be considered as a significant abnormality. Subject has QTcF \\> 450 ms (mean values per parameter will be considered) detected on the 12-lead ECG at Screening or Admission.\n* Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance \\<85 mL/min, using the Cockcroft-Gault formula), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at Screening or Admission.\n* Subject has a history of malignancy within the past 5 years prior to Screening with the exception of excised and curatively treated non-metastatic cell carcinoma of the skin which is considered cured with minimal risk of recurrence.\n* Subject tests positive for SARS-CoV-2 at Admission.\n* Additional exclusion criteria for subjects in the MAD Part in view of lumbar puncture for cerebrospinal fluid (CSF) sampling and the ERP assessment.\n* Subject uses any prescription drugs, herbal supplements, within 4 weeks prior to initial dosing, and/or over-the-counter medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing, other than what is allowed per protocol.\n* Subject received vaccination 1 month before admission or plans to receive vaccination during the study.\n* Use of other investigational drugs/devices within 5 half-lives of the drug from enrollment (time of the subject signing the informed consent form), or within 30 days, whichever is longer.\n* Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing.\n* Plasma donation (\\> 200 mL) within 7 days prior to first dosing.\n* Resting vital signs at Screening (blood pressure \\> 140/90 mmHg, heart rate \\> 90 beats per minute, respiratory rate \\> 20 breaths per minute, and clinically significant elevated body temperature), or any clinically significant abnormalities in vital signs requiring intervention in the opinion of the Investigator. Up to 2 repeat measurements are permitted to confirm eligibility.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Hakop Gevorkyan, MD, MBA",
                    "role": "CONTACT",
                    "phone": "818-254-1600",
                    "phoneExt": "+1",
                    "email": "Mike.Proshyan@parexel.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Hakop Gevorkyan, MD, MBA",
                    "affiliation": "Parexel",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Parexel Los Angeles Early Phase Clinical Unit",
                    "status": "RECRUITING",
                    "city": "Glendale",
                    "state": "California",
                    "zip": "91206",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hakop Gevorkyan, MD, MBA",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Hakop Gevorkyan, MD, MBA",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.14251,
                        "lon": -118.25508
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                },
                {
                    "id": "D000060825",
                    "term": "Cognitive Dysfunction"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000003072",
                    "term": "Cognition Disorders"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29705",
                    "name": "Cognitive Dysfunction",
                    "asFound": "Cognitive Dysfunction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6301",
                    "name": "Cognition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}